Professor Daniel Palmer BSc, MBChB, FRCP, PhD
North West Cancer Research Fund Professor and Honorary Consultant in Medical Oncology, University of Liverpool
Professor Palmer took his current position of North West Cancer Research Chair in Medical Oncology at the University of Liverpool in 2011.
His research interests relate to HPB cancers (liver, pancreas and biliary tract) and incorporate basic laboratory science, translational research and clinical trials. His laboratory research is currently investigating novel therapeutic approaches to the treatment of HPB cancer through stimulation of anti-tumour immune responses and targeting tumour micro-environment through manipulation of TNF family receptors and ligands. He is a member of the NCRN Upper GI cancers clinical studies group, and the hepatobiliary and pancreatic sub-groups. He has established a portfolio of early phase clinical trials and translational studies in this field as well as making significant contributions to multi-centre phase III trials and is Chief Investigator of NCRN102, a randomized study of Nintedanib for patients with advanced hepatocellular carcinoma (HCC). With Prof Tim Meyer (UCL), he co-designed the UK NCRN TACE-2 trial investigating the addition of sorafenib to transarterial chemo-embolisation for patients with intermediate stage HCC. He conducted the UK’s first trial of autologous dendritic cell vaccination for HCC and this led to the ongoing ImmunoTACE trial, combining immunotherapy with TACE for patients with intermediate stage HCC. He is also Chief Investigator for TACE-3, a multinational randomized Phase II/III trial investigating the immune checkpoint inhibitor, nivolumab, in combination with TACE; and for ARACHNID, a platform trial of durvalumab in combination with different radiotherapy modalities for patients with advanced HCC.